Benjamin R. Schrank

Benjamin R. Schrank

Auto-generated profile, based on publicly available information

Benjamin R. Schrank

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in Nature
Verified
Journal Article
Closed access
PDF file
BSBenjamin R. Schrank
Benjamin R. Schrank
TATomas Aparicio
Tomas Aparicio
YLYinyin Li
Yinyin Li
WCWakam Chang
Wakam Chang
BCBrian T. Chait
Brian T. Chait
JGJean Gautier
Jean Gautier

12 January 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YYYi You
Yi You
YTYu Tian
Yu Tian
Zhaogang YangZhaogang Yang
Zhaogang Yang
JSJunfeng Shi
Junfeng Shi
KKKwang Joo Kwak
Kwang Joo Kwak
ALAndrew S. Lee
Andrew S. Lee

22 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
AGAdam J. Grippin
Adam J. Grippin
CMChristiano Marconi
Christiano Marconi
SCSage Copling
Sage Copling
NLNan Li
Nan Li
CBChen Braun
Chen Braun
SLSteven Lin
Steven Lin
Immune checkpoint inhibitors (ICIs) extend survival in many patients with cancer but are ineffective in patients without pre-existing immunity1,2,3,4,5,6,7,8,9. Although personalized mRNA cancer vaccines sensitize tumours to ICIs by directing immune attacks against preselected antigens, personalized vaccines are limited by complex and time-intensive manufacturing processes10,11,12,13,14. Here we show that mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to ICIs. In preclinical models, SARS-CoV-2 mRNA vaccines led to a substantial increase in type I interferon, enabling innate immune cells to prime CD8+ T cells that target tumour-associated antigens. Concomitant ICI treatment is required for maximal efficacy in immunologically cold tumours, which respond by increasing PD-L1 expression. Similar correlates of vaccination response are found in humans, including increases in type I interferon, myeloid–lymphoid activation in healthy volunteers and PD-L1 expression on tumours. Moreover, receipt of SARS-CoV-2 mRNA vaccines within 100 days of initiating ICI is associated with significantly improved median and three-year overall survival in multiple large retrospective cohorts. This benefit is similar among patients with immunologically cold tumours. Together, these results demonstrate that clinically available mRNA vaccines targeting non-tumour-related antigens are potent immune modulators capable of sensitizing tumours to ICIs.

19 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SDShiyan Dong
Shiyan Dong
XLXuan Liu
Xuan Liu
YBYe Bi
Ye Bi
YWYifan Wang
Yifan Wang
AAAbin Antony
Abin Antony
WJWen Jiang
Wen Jiang
The recent success of mRNA therapeutics against pathogenic infections has increased interest in their use for other human diseases including cancer. However, the precise delivery of the genetic cargo to cells and tissues of interest remains challenging. Here, we show an adaptive strategy that enables the docking of different targeting ligands onto the surface of mRNA-loaded small extracellular vesicles (sEVs). This is achieved by using a microfluidic electroporation approach in which a combination of nano- and milli-second pulses produces large amounts of IFN-γ mRNA-loaded sEVs with CD64 overexpressed on their surface. The CD64 molecule serves as an adaptor to dock targeting ligands, such as anti-CD71 and anti-programmed cell death-ligand 1 (PD-L1) antibodies. The resulting immunogenic sEVs (imsEV) preferentially target glioblastoma cells and generate potent antitumour activities in vivo, including against tumours intrinsically resistant to immunotherapy. Together, these results provide an adaptive approach to engineering mRNA-loaded sEVs with targeting functionality and pave the way for their adoption in cancer immunotherapy applications.

1 November 2008 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
RGReema Goel
Reema Goel
BSBenjamin R. Schrank
Benjamin R. Schrank
SAShikha Arora
Shikha Arora
BBBrian Boylan
Brian Boylan
BFBarbara Fleming
Barbara Fleming
DNDebra K. Newman
Debra K. Newman
Objective— Atherosclerosis is a vascular disease that involves lesion formation at sites of disturbed flow under the influence of genetic and environmental factors. Endothelial expression of adhesion molecules that enable infiltration of immune cells is important for lesion development. Platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31) is an adhesion and signaling receptor expressed by many cells involved in atherosclerotic lesion development. PECAM-1 transduces signals required for proinflammatory adhesion molecule expression at atherosusceptible sites; thus, it is predicted to be proatherosclerotic. PECAM-1 also inhibits inflammatory responses, on which basis it is predicted to be atheroprotective. Methods and Results— We evaluated herein the effect of PECAM-1 deficiency on development of atherosclerosis in LDL receptor–deficient mice. We found that PECAM-1 has both proatherosclerotic and atheroprotective effects, but that the former dominate in the inner curvature of the aortic arch whereas the latter dominate in the aortic sinus, branching arteries, and descending aorta. Endothelial cell expression of PECAM-1 was sufficient for its atheroprotective effects in the aortic sinus but not in the descending aorta, where the atheroprotective effects of PECAM-1 also required its expression on bone marrow–derived cells. Conclusion— We conclude that PECAM-1 influences initiation and progression of atherosclerosis both positively and negatively, and that it does so in a site-specific manner.

23 December 2022 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
JZJennifer Zagelbaum
Jennifer Zagelbaum
ASAllana Schooley
Allana Schooley
JZJunfei Zhao
Junfei Zhao
BSBenjamin R. Schrank
Benjamin R. Schrank
ECElsa Callen
Elsa Callen
JGJean Gautier
Jean Gautier
Nuclear actin-based movements have been shown to orchestrate clustering of DNA double-strand breaks (DSBs) into homology-directed repair domains. Here we describe multiscale three-dimensional genome reorganization following DNA damage and analyze the contribution of the nuclear WASP-ARP2/3-actin pathway toward chromatin topology alterations and pathologic repair. Hi-C analysis reveals genome-wide, DNA damage-induced chromatin compartment flips facilitated by ARP2/3 that enrich for open, A compartments. Damage promotes interactions between DSBs, which in turn facilitate aberrant, actin-dependent intra- and inter-chromosomal rearrangements. Our work establishes that clustering of resected DSBs into repair domains by nuclear actin assembly is coordinated with multiscale alterations in genome architecture that enable homology-directed repair while also increasing nonhomologous end-joining-dependent translocation frequency.